We are live on ! Find out more
ARTV

Artiva Biotherapeutics
ARTV

53 hedge funds and large institutions have $62.8M invested in Artiva Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 12

1.24% less ownership

Funds ownership: 87.12% → 85.88% (-1.2%)

7% less funds holding

Funds holding: 57 → 53 (-4)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

71% less capital invested

Capital invested by funds: $213M → $62.8M (-$150M)

Holders
53
Holders Change
-4
Holders Change %
-7.02%
% of All Funds
0.71%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
3
Increased
23
Reduced
12
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.08M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$511K
3
Citadel Advisors
Citadel Advisors
Florida
+$224K
4
N
Nuveen
North Carolina
+$158K
5
SEI Investments
SEI Investments
Pennsylvania
+$158K

Top Sellers

Rank Fund Capital Flow
1
VP
venBio Partners
California
-$1.73M
2
RI
RTW Investments
New York
-$1.5M
3
CAM
Cormorant Asset Management
Massachusetts
-$1.04M
4
EC
EcoR1 Capital
California
-$418K
5
Norges Bank
Norges Bank
Norway
-$302K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$73.1K +$131K +24,357 New
Barclays
27
Barclays
United Kingdom
$68.3K -$7.6K -1,408 -6%
Deutsche Bank
28
Deutsche Bank
Germany
$64.3K – – –
JP Morgan Chase
29
JP Morgan Chase
New York
$53.6K -$107K -19,736 -52%
RhumbLine Advisers
30
RhumbLine Advisers
Massachusetts
$43.5K +$8.71K +1,614 +13%
Citigroup
31
Citigroup
New York
$43K -$6.85K -1,268 -8%
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$39.7K +$18.1K +3,351 +34%
Wells Fargo
33
Wells Fargo
California
$38K +$21.8K +4,043 +47%
IIM
34
INTECH Investment Management
Florida
$34.6K +$62.3K +11,547 New
Mirae Asset Global ETFs Holdings
35
Mirae Asset Global ETFs Holdings
Hong Kong
$34.4K +$18.6K +3,438 +43%
CF
36
Corebridge Financial
Texas
$29.2K +$13.2K +2,449 +34%
Bank of America
37
Bank of America
North Carolina
$24.9K -$13.6K -2,521 -23%
CUAMC
38
China Universal Asset Management Company
China
$14.6K -$1.5K -278 -5%
Fidelity Investments
39
Fidelity Investments
Massachusetts
$10.7K +$14.3K +2,655 +295%
PFSRSONJ
40
Police & Firemen's Retirement System of New Jersey
New Jersey
$10.4K – – –
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
$8.81K – – –
TRCT
42
Tower Research Capital (TRC)
New York
$7.84K +$7.57K +1,402 +116%
Legal & General Group
43
Legal & General Group
United Kingdom
$6.05K +$3.37K +625 +45%
AIP
44
Ameritas Investment Partners
Nebraska
$4.27K – – –
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$3.12K – – –
Mirae Asset Global Investments
46
Mirae Asset Global Investments
South Korea
$2.57K +$22 +4 +0.5%
GFM
47
GF Fund Management
China
$1.81K +$502 +93 +18%
MSFP
48
Mark Sheptoff Financial Planning
Connecticut
$1.2K -$2.7K -500 -56%
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$1K -$3.39K -628 -57%
AB
50
Amalgamated Bank
New York
$1K – – –
1
2
3

ARTV Hedge Fund Activity: Q1 2025 in Review

53 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q1 2025, worth a combined $62.8M — down 71% from $213M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of ARTV and 3 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 23 added.

The largest buyer was BlackRock, adding an estimated $1.08M. The largest seller was venBio Partners, cutting an estimated $1.73M.

  • 53 institutional investors held Artiva Biotherapeutics (ARTV) as of Q1 2025, down from 57 in Q4 2024.
  • Funds reported $62.8M of Artiva Biotherapeutics stock for Q1 2025, down 71% quarter-over-quarter.
  • 3 funds opened new Artiva Biotherapeutics positions in Q1 2025 and 7 closed out, a net change of -4 holders.
  • The largest Artiva Biotherapeutics buyer in Q1 2025 was BlackRock, an estimated $1.08M added.
  • The largest Artiva Biotherapeutics seller in Q1 2025 was venBio Partners, an estimated $1.73M sold.

Based on aggregated 13F filings for Q1 2025.